Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics Inc. has demonstrated a robust growth trajectory, with a year-over-year increase of 57% in the central nervous system (CNS) segment, supported by a higher-than-expected mix of new patient starts (NPS) in the pharmacy channel. The management's decision to raise 2025 and 2026 revenue estimates to $97.5 million and $136 million, respectively, reflects strong momentum in new prescriptions and the successful expansion of sales territories. Additionally, the company is well-positioned for sustained growth, projecting a compound annual growth rate (CAGR) of 30-40% from 2024 to 2028, further bolstered by a solid quarter of financial performance and an increase in revenue guidance.

Bears say

Beta Bionics faces significant risks that could adversely affect its financial performance, particularly following the disappointing launch of the iLet Bionic Pancreas amid competitive pressures, which may hinder market share and revenue growth. Delays in clinical development timelines could further obstruct the company's ability to penetrate pharmacy channels effectively and may necessitate additional capital investments, potentially leading to shareholder dilution. Furthermore, pending Medicare payment model proposals and regulatory uncertainties threaten to create additional headwinds, contributing to a negative outlook for the company’s stock.

BBNX has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 10 analysts, BBNX has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.